Woodland International Research Group
Woodland International Research Group
Little Rock, Arkansas, United States14 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Brenipatide in Participants With Alcohol Use Disorder | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07219953 | |
| A Study of Brenipatide in Participants With Opioid Use Disorder | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-10-07 | NCT07420283 | |
| A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07219966 | |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06701903 | |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-22 | NCT06951698 | |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT06929273 | |
| 52-week Open Label Safety-Tolerability Study | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-09 | NCT07369154 | |
| An Open-Label Study of Azetukalner in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-03 | NCT06922110 | |
| An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | Bipolar and Related Disorders, bipolar I disorder, bipolar II disorder, bipolar disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-02 | NCT07217860 | |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Bipolar and Related Disorders, bipolar I disorder, bipolar II disorder, bipolar disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-02 | NCT07172516 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-03 | NCT06775379 | |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-07-27 | NCT07363577 | |
| Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-07-15 | NCT02736656 | |
| A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia | Cognition Disorders, Cognitive Dysfunction, Schizophrenia Spectrum and Other Psychotic Disorders, cognitive disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 2 | 2026-06-23 | NCT07191483 |